A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

I3Y-MC-JPCU -

The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastaticbreast cancer that has spread to internal organs.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
No
Enrollment Goal
4
Trial Dates
Aug 14, 2019 - Aug 11, 2020
How long will I be in the trial?
Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond.
Trial Phase
IV

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.